Best Life Sciences Companies in San Mateo, United States
The 49 best Life Sciences companies in San Mateo, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Rakuten Medical.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in San Mateo
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Rakuten Medical Developer of a photoimmunotherapy platform for treating cancer 69Funding top 12%Moat top 24%Patents top 25%Innovation top 34% All 10 signals ▾Fundingtop 12% Moattop 24% Patentstop 25% Innovationtop 34% Growthtop 35% Newstop 39% Markettop 45% Techtop 46% Talentbottom 49% Globalbottom 42% Funding: Raised $874M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 150 patents rank vs industry peers · Fliar Intelligence Index 69/100 | $874M | 13 mo ago | 110 110 → 129 (+17%) | Hiroshi Mikitani Chairman & CEO | WordPressApple iCloud MailMySQL+27 | 150 patents Photodynamic therapy delivery devices and catheter systems for targeted cancer treatment | — |
| 2 | EndoGastric Solutions Endoluminal solutions for digestive diseases, restoring anatomy and improving patient outcomes | $355M | 56 mo ago | 80 | — | WordPressMySQLPHP+21 | 202 patents Surgical devices for gastro‑esophageal valve formation and tissue fastening | — |
| 3 | Kronos Bio Developer of small molecule based therapeutics for cancer treatment | $271M | 71 mo ago | 97 | Norbert Bischofberger President and CEO | — | — | — |
| 4 | Terns Pharmaceutical Developer of therapies for treating liver disease and cancer | $208M | 67 mo ago | 46 46 → 66 (+43%) | — | WordPressApple iCloud MailMicrosoft 365+27 | — | — |
| 5 | Cargo Therapeutics Developer of cell-based therapeutics for cancer treatment | $200M | 42 mo ago | 42 42 → 28 (-33%) | Louai Labanieh Co-Founder | DrupalApple iCloud MailMicrosoft 365+31 | — | — |
| 6 | Allakos Develop therapeutic antibodies for the treatment of allergic, inflammatory, and proliferative diseases | $160M | 83 mo ago | 123 | Robert Alexander CEO | DrupalApple iCloud MailMicrosoft 365+23 | 188 patents Therapeutic antibodies targeting Siglec receptors for inflammatory and gastrointestinal diseases | — |
| 7 | Route 92 Medical Developer of next-generation products for neurointerventional procedures 69Funding top 14%Innovation top 18%Patents top 21%Moat top 29% All 10 signals ▾Fundingtop 14% Innovationtop 18% Patentstop 21% Moattop 29% Growthtop 32% Techtop 50% Talentbottom 49% Marketbottom 45% Newsbottom 41% Globalbottom 40% Funding: Raised $138M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) Innovation: 223 patents (top 12% of patent-holders) · 137 filings since 2022 vs 82 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $138M | 6 mo ago | 51 | Tony Chou Founder & CEO | WordPress Block EditorWordPressMySQL+23 | 223 patents Neurovascular aspiration catheters for minimally invasive thrombectomy procedures | — |
| 8 | PrognomiQ Developer of tests for the detection and treatment of cancer and other diseases 57Funding top 17%Patents top 25%Moat top 28%Innovation top 31% All 9 signals ▾Fundingtop 17% Patentstop 25% Moattop 28% Innovationtop 31% Talenttop 38% Techtop 44% Globalbottom 40% Marketbottom 34% Newsbottom 18% Funding: Raised $135M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 70 patents matched (strict assignee match) · 68 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $135M | 7 mo ago | 24 24 → 44 (+83%) | Philip Ma Co-Founder & CEO | WordPressMarkerApple iCloud Mail+30 | 70 patents AI-driven multi-omic cancer diagnostics and biomarker quantification platforms | — |
| 9 | Aimmune Therapeutics Provider of desensitization treatments for food allergies such as peanuts, egg and milk | $97M | 78 mo ago | 250 | Andrew Oxtoby CEO | — | — | — |
| 10 | Afferent Pharmaceuticals Targeting sensitized nerves to treat chronic & debilitating neurogenic disorders. | $78M | 133 mo ago | 5 | — | — | 130 patents P2X3/P2X2/3 antagonist pyrimidine drugs for chronic cough therapy | — |
| 11 | CuraSen Provider of therapeutics for neurodegenerative disorder | $60M | 23 mo ago | 16 | Mehrdad Shamloo Co-Founder | — | — | — |
| 12 | Sonitus Medical Online pharmacy providing affordable generic and brand medications globally | $58M | 147 mo ago | 45 | — | — | 292 patents Intra‑oral acoustic communication and hearing‑aid devices with vibration/audio processing | — |
| 13 | Vium Provider of living informatics platform for preclinical in vivo drug research | $57M | 97 mo ago | 51 | — | — | 77 patents Automated animal research instrumentation and data platforms for physiological monitoring. | — |
| 14 | Juvena Therapeutics Company developing protein based therapies for sarcopenia and muscle regeneration 29Funding top 25%Moat top 31%Talent top 38%News bottom 42% All 7 signals ▾Fundingtop 25% Moattop 31% Talenttop 38% Newsbottom 42% Globalbottom 39% Marketbottom 34% Techbottom 28% Funding: Raised $50.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $50M | 13 mo ago | 30 | Jeremy O'Connell Co-Founder & CSO | WordPressMySQLPHP+16 | — | — |
| 15 | Nuon Therapeutics Anti-aging therapeutics news, data directory, and small business aggregator | $48M | 192 mo ago | — | Rodney Pearlman CEO | — | — | — |
| 16 | Sonomotion Developer of a non-invasive medical device for kidney stone treatment | $42M | 15 mo ago | 9 | Bryan Cunitz Co-Founder | WordPressMySQLPHP+12 | 8 patents Focused ultrasonic propulsion probes and radiation-force control for therapeutic ultrasound applications | — |
| 17 | AusperBio Developer of therapies for the treatment of chronic hepatitis B and other major infectious diseases 40Funding top 26%Talent top 38%Moat top 39%Growth bottom 42% All 7 signals ▾Fundingtop 26% Talenttop 38% Moattop 39% Growthbottom 42% Marketbottom 40% Globalbottom 38% Newsbottom 24% Funding: Raised $37.0M across 4 rounds · 4 rounds over 2 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $37M | 10 mo ago | — | Guofeng Cheng Co-Founder & CEO | — | — | — |
| 18 | Levita Magnetics Developer of robotic surgical devices | $26M | 5 mo ago | 1 | Alex Seelenberger Co-Founder | WordPressMySQLPHP+24 | 81 patents Magnetically guided surgical instruments for minimally invasive operating room procedures | — |
| 19 | Roam Machine learning platform for health data analysis | $22M | 123 mo ago | 26 | — | — | 24 patents Patents concentrated in computing, sensing & instrumentation | — |
| 20 | Itero Biopharmaceuticals Developing recombinant follicle stimulating hormone to treat female infertility. | $21M | 218 mo ago | 73 | Bryan Lawlis Founder & CEO | — | 19 patents Preservative‑free follicle‑stimulating hormone self‑injection delivery devices | — |
| 21 | SONITUS Technologies Sensory interface platform enabling voice connectivity in extreme conditions | $17M | 103 mo ago | 8 | — | WordPressMySQLPHP+27 | — | — |
| 22 | MVRx Developer of an implant for treating functional mitral regurgitation | $13M | 75 mo ago | — | David Rahdert Co-Founder | — | 111 patents Cardiac valve annulus reshaping tools and advanced suture management devices | — |
| 23 | TheraVida Developing innovative therapies for hyperhidrosis, improving patient lives | $13M | 41 mo ago | 2 | Ben McGraw CEO & Chairman | — | 157 patents Pharmaceutical formulations for treating hyperhidrosis and overactive bladder conditions. | — |
| 24 | Maverix NGS data analysis solutions enabling better science and healthcare advancements | $8M | 120 mo ago | 14 | David Mandelkern Co-Founder | — | — | — |
| 25 | Cellular Vehicles Developer of process automation tools for cell-based therapy manufacturing | $295K | 26 mo ago | 7 | — | — | 11 patents Cellular therapy infusion systems and microfluidic devices for preparing and delivering cell suspensions | — |
| 26 | Bespoke Developer of immunotherapies against cancers | $256K | 49 mo ago | — | Kirk Trisler Co-Founder | — | 48 patents Personalized eyewear design and fitting using 3D facial scans and optical measurements | — |
Top 12 Life Sciences companies in San Mateo
#1
Series F · San Mateo, California · founded 2015 · 51 employees$137.7Mraised▾
Developer of next-generation products for neurointerventional procedures. The company's products include the FreeClimb Catheter Systems, which are advanced neurointervention systems to provide superior performance, and the Monopoint Reperfusion System to streamline delivery and enable super-bore aspiration at the most common stroke targets.
- Jan 2026Series F$50M
- Jun 2024Series F$50.4M
- Nov 2023Series F$31.3M
- Dec 2021Conventional Debt$55M
#2
Series F · San Mateo, California · founded 2013 · 110 employees$874.3Mraised▾
Developer of a photoimmunotherapy platform for treating cancer. The company claims that it is developing a technology that combines antibodies with laser-activated precision. The technology induces tumour cell death by inducing an immune response. The company has developed ASP-1929 program for recurrent head and neck squamous cell carcinoma (rHNSCC) and for other cancer types.
- Jul 2025Series F$111.5M
- Mar 2024Series E$119M
- Sep 2023Series D$104.8M
- Dec 2022Series D$70M
#3
Series D · San Mateo, California · founded 2020 · 24 employees$135Mraised▾
Developer of tests for the detection and treatment of cancer and other diseases. The company's products use proteomic data with genomic, metabolomic, and other health data for early disease detection.
- Jan 2026Series D$11.9M
- Aug 2025Series D$10M
- Aug 2024Series D$34.3M
- Mar 2022Series C$46M
#4
Series D · San Mateo, California · founded 2011 · 1 employees$26Mraised▾
Developer of robotic surgical devices. The company is developing a magnetic surgical platform designed to magnetically retract and maneuver the gallbladder, eliminating the need for a dedicated trocar and shafted instrumentation. It's a technological platform that utilizes magnetic retraction designed to grasp and retract the gallbladder in laparoscopic cholecystectomy procedures.
- Feb 2026Series D$30.7M
- Aug 2022Series C$26M
- Jul 2019Seed$1M
#5
Series B · San Mateo, California · founded 2019$37Mraised▾
Developer of therapies for the treatment of chronic hepatitis B and other major infectious diseases. It offers a pipeline of oligonucleotide therapeutics, including AHB-137 based on conjugation technology for targeted delivery and integrating DNA replication inhibitors, HBsAg inhibitors, and immunomodulators.
- Sep 2025Series B$63M
- May 2025Series B$50M
- Dec 2024Series B$73M
- Jul 2024Series A$37M
#6
Series B · San Mateo, California · founded 2017 · 30 employees$50Mraised▾
Juvena Therapeutics is engaged in the development of protein-based therapeutics that promote tissue generation in the elderly. The company has developed a discovery platform for screening restored muscle function which can be developed to other tissue types. The company has developed a protein cocktail which can improve the ability of aged muscle to heal and regenerate and also to look youthful and active.
- Jun 2025Series B$41M
- Nov 2022Series A$41M
- Sep 2021Grant (prize money)$254.3K
- Feb 2018Series A$4.3M
#7
Series C · San Mateo, California · founded 2014 · 9 employees$41.8Mraised▾
Developer of a non-invasive medical device for kidney stone treatment. The products of the company include Break Wave an ultrasound solution that fragments kidney stones non-invasively and Stone Clear a non-invasive ultrasound-based tool to reposition kidney stones within the kidney and ureter.
- Apr 2025Grant (prize money)$2.2M
- Feb 2025Grant (prize money)$278.2K
- Nov 2022Series C$12.4M
- Apr 2022Series B$11.5M
#8
Series B · San Mateo, California · founded 2013 · 16 employees$59.8Mraised▾
CuraSen develops drugs for neurodegenerative disorders like inflammation, proteinopathy and neuronal atrophy, Alzheimer’s, and Parkinson’s diseases. It is involved in developing small molecules and targets innate homeostatic pathways.
- Aug 2024Series B$5.8M
- Oct 2023Series B—
- Oct 2018Series A$54M
#9
Series J · San Mateo, California · founded 2002 · 80 employees$355.2Mraised▾
Endoluminal solutions for digestive diseases, restoring anatomy and improving patient outcomes. They specialize in minimally invasive therapies for gastroesophageal reflux disease (GERD), offering innovative medical devices and procedures designed to restore the natural state of the anatomy. Their flagship technology provides a lower side-effect profile compared to alternative options, improving the quality of life for patients. They are committed to training and education for healthcare providers, ensuring proper technique and optimal patient results. They focus on community outreach and adhere to regulatory labeling standards, prioritizing patient safety and ethical practices. They offer a comprehensive approach to GERD treatment, providing support and resources for both patients and providers.
- Dec 2021Series J$27M
- May 2019Series I$14.5M
- Jul 2018Series I$30.5M
- Jun 2018Series H$25.5M
#10
Acquired · San Mateo, California · founded 2021 · 42 employees$200Mraised▾
Developer of cell-based therapeutics for cancer treatment. It offers CAR T-cell therapies which include CD22 CAR T, and Multi-Specific CAR T drug candidates for the treatment of hematological malignancies, and solid tumors.
- Feb 2023Series A$200M
#11
Acquired · San Mateo, California · founded 2017 · 97 employees$271Mraised▾
Developer of small molecule-based therapeutics for cancer treatment. The company has developed small molecules that bind or interfere with the target protein activity directly, disrupt protein-protein complexes, or affect nearest neighbor proteins that may indirectly modulate target activity.
- Aug 2020Series B$148M
- Jul 2019Series A$105M
- May 2018Seed$18M
#12
Acquired · San Mateo, California · founded 2017 · 46 employees$207.7Mraised▾
Developer of therapies for treating liver disease and cancer. The lead candidate TERN 101 is a Farnesoid X Receptor agonist (nuclear receptor expressed in high amount), other candidates are TERN 201, TERN 501, and GLP-1R-agonist. These are used for treating Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD).
- Jan 2021Series C$97.7M
- Oct 2018Series B$80M
- Apr 2018Series A$30M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.